Bausch Health
BHC
#3644
Rank
C$4.10 B
Marketcap
$11.14
Share price
-2.57%
Change (1 day)
17.40%
Change (1 year)
Bausch Health is a Canadian company that researches, develops and produces pharmaceuticals and markets patented drugs, generics and non-prescription drugs in the areas of dermatology and ophthalmology.

P/E ratio for Bausch Health (BHC)

P/E ratio as of November 2024 (TTM): -3.04

According to Bausch Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.04459. At the end of 2022 the company had a P/E ratio of -10.1.

P/E ratio history for Bausch Health from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-10.1-2.64%
2021-10.4-21.2%
2020-13.2123.59%
2019-5.90277.72%
2018-1.56-151.61%
20173.02-244.13%
2016-2.10-98.41%
2015-132-350.91%
201452.6-216.52%
2013-45.2-72.05%
2012-162-279.91%
201189.8-475.44%
2010-23.9-290.16%
200912.666.36%
20087.56-31.48%
200711.0-31.18%
200616.04.03%
200515.4-6.78%
200416.5-119.23%
2003-86.0-295.29%
200244.0-50.7%
200189.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.9953-67.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.91 94.03%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.